Galmed Pharmaceuticals (NASDAQ:GLMD) Raised to Hold at Wall Street Zen

Galmed Pharmaceuticals (NASDAQ:GLMD) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Monday.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ GLMD opened at $1.45 on Monday. The company has a market cap of $2.39 million, a P/E ratio of -0.09 and a beta of 0.58. The firm’s fifty day moving average is $1.77 and its two-hundred day moving average is $1.82. Galmed Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $23.80.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Thursday, May 22nd. The biopharmaceutical company reported ($0.62) EPS for the quarter.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.